GLUE
NASDAQ HealthcareMonte Rosa Therapeutics, Inc. - Common Stock
Biotechnology
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $19.78 |
|---|---|
| 成交量 | 880,015 |
| 市值 | 1.58B |
| 贝塔系数 | 1.640 |
| RSI（14日） | 85.9 超买 |
| 200日均线 | $12.88 |
| 50日均线 | $17.54 |
| 52周最高 | $25.77 |
| 52周最低 | $3.51 |
| Forward P/E | -11.63 |
| Price / Book | 5.56 |
🎯 投资策略评分
GLUE 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (86/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GLUE in your text
粘贴任何文章、记录或帖子 — 工具将提取 GLUE 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.